Wegovy Novo Nordisk by the International Energy Agency due to the lack of disclosure of payments for UK health groups | Pharmaceutical
Medicine monitoring has reprimanded Wegovy Maker Novo Nordisk for its failure to properly reveal dozens of payments to the UK health sector, where it sought to boost sales of slimming drugs.
Danish drug giant-the most valuable company in Europe-systematically or not built by reporting or did not reveal the funding provided for more than seven years for pharmacy companies, charitable societies for obesity, training providers, professional bodies and patient groups.
Even after admitting errors and conducting an internal review, she failed to report them accurately. The company has now been officially reprimanded by the PMCPA, which it said made this industry in a bad condition.
In finding 48 violations of the Industry Law, she said that the serious compliance failures – which were committed while Novo Nordsek was already the subject of audit after previous violations – “raised questions about the company’s culture and showed bad ruling and lack of care.”
“Through the failure to publicly reveal payments, report unacuvantance payments and abuse health care organizations and patient organizations over a long period of time,” he said, “It has brought a reputation and reduces confidence in the pharmaceutical industry.”
The PMCPA committee said that the company was not referred for more penalties because it was already punished due to similar violations and is undergoing an ongoing audit.
The payments that have not been revealed after an investigation by academics in the United Kingdom and Sweden have emerged who have been disclosed by Nouvo Nordsk with financial statements and other records of health care organizations in the United Kingdom.
The company was It was previously accepted to properly detect paymentsThe PMCPA told 2023 that it had deleted more than 500 transactions worth 7.8 million pounds to more than 150 organizations between 2020 and 2022.
This was later found in a violation of the PMCPA, who said in July there was “basic governance failures”.
But the investigation conducted by researchers at Bath and Wind universities, which interfered with the PMCPA probe, found that even after an internal review and demanding the problem corrected, Novo Nordisk failed to register more total payments with a total of 635,000 pounds to 30 organizations.
They filed a 130 -page complaint to the PMCPA, which said on Friday ruling that Novo Nordsek has repeatedly broke the Industry Law on payments, from 2015 to 2022.
This included 183,000 pounds in unannounced financing for a weight loss training company that participates in pharmacies and NHS and caring for seminars via the Internet provided by the medical training provider and granted to charities and the royal college. The payment of 338,435 pounds to the Global Obesity Organization has been detected incorrectly.
Dr. Emily Ricard, who led the research in Bath, said it was “interesting” that no mistakes have been taken in the private Novo Nordsk review. This was “particularly disturbing”, since they coincided with the UK’s launch of famous weight loss drugs like Wegovy. ” About transparency and accountability. “
“When Novo Nordsek does not reveal payments, it is not only destroyed for its reputation – it undermines confidence in the entire health care system,” said Dr. Piotr Oziraneski, Ricard Fellow in Bath.
After promoting the newsletter
Novo Nordisk said it was “dedicated to work transparently and morally” and began to report “these historical transfers of value seriously.” He said he had put a voluntary mark on most of the same missed disclosures, and others have been accurately revealed, adding that he was “committed to adhering to” the symbol of industry and maintaining the highest moral suffering.
The ruling against Novo Nordsek follows a series of investigations into the tactics used by the Wegov maker to promote drugs. observer She previously revealed how Novo Nordisk has paid experts who continued to promote their drugs in the emergence of the media without always clarifying their financial interests. It also funded the NHS weight loss services and provided hundreds of thousands of pounds to pharmacies, including shoes and LLOYDS.
The researchers said the latest results showed the need for “comprehensive reform” of pharmaceutical spending control systems in Britain.
There is no legal condition for companies to detect payments for the health care sector, but many of the participation in the industry law that requires them to be reported through a volunteer plan called the UK disclosure.
The alleged violations are evaluated by PMCPA, which can impose penalties, including general reprimand or the company’s claim to publish a correction statement. It can also report the company to the ABPI Council, which may attach or expel the company from the association.
Critics say this is not enough. They are calling for a government central database for payment reports, which can be accessed to the public, with strict enforcement and penalties for non -compliance. “Transparency in the UK pharmaceutical industry is transparency by name only. Urgent need is a comprehensive reform.
The British Pharmaceutical Industry Association, which represents the pharmaceutical companies, rejected the comment, but Dr. Amit Aguar, Director of Medical Affairs, said that the case was evidence that the self -regulatory system “maintains companies.”
“We are thinking about options to increase transparency and will determine the next steps soon,” said the Ministry of Health.